Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: a systematic review and economic evaluation

P Sharma; D Boyers; C Boachie; F Stewart; Z Miedzybrodzka; W Simpson; M Kilonzo; P McNamee; G Mowatt

doi:10.3310/hta16170

Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: a systematic review and economic evaluation

P Sharma, D Boyers, C Boachie, F Stewart, Z Miedzybrodzka, W Simpson, M Kilonzo, P McNamee, G Mowatt

Research output: Contribution to journal › Article › peer-review

22 Citations (Scopus)

17 Downloads (Pure)

Abstract

Familial hypercholesterolemia (FH) is an autosomal dominant genetic condition causing a high risk of coronary heart disease. The prevalence of this disease is about 1 in 500 in the UK, affecting about 120,000 people across the whole of the UK. Current guidelines recommend DNA testing, however, these guidelines are poorly implemented, therefore 102,000 or 85% of this group remain undiagnosed.

Original language	English
Pages (from-to)	1-266
Number of pages	266
Journal	Health Technology Assessment
Volume	16
Issue number	17
DOIs	https://doi.org/10.3310/hta16170
Publication status	Published - Mar 2012

Bibliographical note

PMID: 22469073 [PubMed - indexed for MEDLINE] Free full text

Access to Document

10.3310/hta16170

Sharma 2012
Sharma, P, Boyers, D, Boachie, C, Stewart, F, Miedzybrodzka, Z, Simpson, W, Kilonzo, M, McNamee, P & Mowatt, G 2012, 'Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: a systematic review and economic evaluation', Health Technology Assessment, vol 16, no. 17, pp. 1-266.
Final published version, 2.13 MB

http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0041807/

Cite this

@article{b1574e1854f5440a8596ee13f4a6d056,

title = "Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: a systematic review and economic evaluation",

abstract = "Familial hypercholesterolemia (FH) is an autosomal dominant genetic condition causing a high risk of coronary heart disease. The prevalence of this disease is about 1 in 500 in the UK, affecting about 120,000 people across the whole of the UK. Current guidelines recommend DNA testing, however, these guidelines are poorly implemented, therefore 102,000 or 85% of this group remain undiagnosed.",

author = "P Sharma and D Boyers and C Boachie and F Stewart and Z Miedzybrodzka and W Simpson and M Kilonzo and P McNamee and G Mowatt",

note = "PMID: 22469073 [PubMed - indexed for MEDLINE] Free full text",

year = "2012",

month = mar,

doi = "10.3310/hta16170",

language = "English",

volume = "16",

pages = "1--266",

journal = "Health Technology Assessment",

issn = "2046-4924",

publisher = "National Co-ordinating Centre for HTA",

number = "17",

}

TY - JOUR

T1 - Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia

T2 - a systematic review and economic evaluation

AU - Sharma, P

AU - Boyers, D

AU - Boachie, C

AU - Stewart, F

AU - Miedzybrodzka, Z

AU - Simpson, W

AU - Kilonzo, M

AU - McNamee, P

AU - Mowatt, G

N1 - PMID: 22469073 [PubMed - indexed for MEDLINE] Free full text

PY - 2012/3

Y1 - 2012/3

N2 - Familial hypercholesterolemia (FH) is an autosomal dominant genetic condition causing a high risk of coronary heart disease. The prevalence of this disease is about 1 in 500 in the UK, affecting about 120,000 people across the whole of the UK. Current guidelines recommend DNA testing, however, these guidelines are poorly implemented, therefore 102,000 or 85% of this group remain undiagnosed.

AB - Familial hypercholesterolemia (FH) is an autosomal dominant genetic condition causing a high risk of coronary heart disease. The prevalence of this disease is about 1 in 500 in the UK, affecting about 120,000 people across the whole of the UK. Current guidelines recommend DNA testing, however, these guidelines are poorly implemented, therefore 102,000 or 85% of this group remain undiagnosed.

U2 - 10.3310/hta16170

DO - 10.3310/hta16170

M3 - Article

C2 - 22469073

SN - 2046-4924

VL - 16

SP - 1

EP - 266

JO - Health Technology Assessment

JF - Health Technology Assessment

IS - 17

ER -

Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: a systematic review and economic evaluation

Abstract

Bibliographical note

Access to Document

Fingerprint

Cite this